MIT study reveals why immunotherapy doesn’t work for all cancer patients

Beginning next year, ob/gyn programs will start using an independent system for processing residency applications, rather than the Electronic Residency Application Service (ERAS). The joint

As­cle­tis’ sub­sidiary Gan­nex re­vealed that its non-al­co­holic steato­hep­ati­tis (NASH) drug can­di­date sig­nif­i­cant­ly re­duced av­er­age lev­els of liv­er fat in pa­tients en­rolled in a mid-stage tri­al,